VenoValve to be Highlighted at Charing Cross Symposium

EnVVeno Medical Corporation, a leader in deep venous disease treatment innovation, has announced that its pioneering product, the VenoValve, will be featured at the 47th Annual Charing Cross Symposium in London. Dr. David Dexter will present on the progress and future of invasive treatments for deep venous reflux. His presentation is scheduled for April 24, 2025, at 11:10 AM BST.

The VenoValve is designed as a surgical replacement for venous valves in patients suffering from severe deep venous Chronic Venous Insufficiency (CVI). EnVVeno estimates that 2.5 million Americans annually could benefit from this device. A decision on its pre-market authorization by the FDA is expected in late 2025.

Severe CVI, a condition caused by vein valve failure, leads to significant symptoms like leg swelling and ulcers. It affects daily life and mental well-being. The widespread impact results in high treatment costs exceeding $4 billion annually in the U.S.